Novo Nordisk A/S (NVO)
129.15
+0.84
(+0.65%)
USD |
NYSE |
May 01, 16:00
130.80
+1.65
(+1.28%)
After-Hours: 18:18
Novo Nordisk Cash from Operations (Quarterly): 1.302B for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.302B |
| September 30, 2023 | 5.975B |
| June 30, 2023 | 4.234B |
| March 31, 2023 | 4.300B |
| December 31, 2022 | 1.464B |
| September 30, 2022 | 2.912B |
| June 30, 2022 | 3.249B |
| March 31, 2022 | 3.558B |
| December 31, 2021 | -446.39M |
| September 30, 2021 | 3.281B |
| June 30, 2021 | 4.092B |
| March 31, 2021 | 1.825B |
| December 31, 2020 | -174.18M |
| September 30, 2020 | 3.073B |
| June 30, 2020 | 3.583B |
| March 31, 2020 | 1.478B |
| December 31, 2019 | 815.04M |
| September 30, 2019 | 2.449B |
| June 30, 2019 | 2.245B |
| March 31, 2019 | 1.505B |
| December 31, 2018 | 1.266B |
| September 30, 2018 | 1.702B |
| June 30, 2018 | 2.480B |
| March 31, 2018 | 1.619B |
| December 31, 2017 | 713.69M |
| Date | Value |
|---|---|
| September 30, 2017 | 2.268B |
| June 30, 2017 | 1.552B |
| March 31, 2017 | 1.733B |
| December 31, 2016 | 1.609B |
| September 30, 2016 | 2.237B |
| June 30, 2016 | 2.230B |
| March 31, 2016 | 1.105B |
| December 31, 2015 | 1.501B |
| September 30, 2015 | 1.814B |
| June 30, 2015 | 1.759B |
| March 31, 2015 | 621.90M |
| December 31, 2014 | 1.315B |
| September 30, 2014 | 2.096B |
| June 30, 2014 | 1.494B |
| March 31, 2014 | 746.96M |
| December 31, 2013 | 963.64M |
| September 30, 2013 | 1.141B |
| June 30, 2013 | 1.263B |
| March 31, 2013 | 1.251B |
| December 31, 2012 | 361.06M |
| September 30, 2012 | 1.276B |
| June 30, 2012 | 1.214B |
| March 31, 2012 | 985.15M |
| December 31, 2011 | 693.76M |
| September 30, 2011 | 1.439B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-446.39M
Minimum
Dec 2021
5.975B
Maximum
Sep 2023
2.590B
Average
2.912B
Median
Sep 2022
Cash from Operations (Quarterly) Benchmarks
| Amgen Inc | 538.00M |
| AstraZeneca PLC | 2.486B |
| Vertex Pharmaceuticals Inc | 234.60M |
| Viking Therapeutics Inc | -6.134M |
| Evaxion Biotech AS | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -2.112B |
| Cash from Financing (Quarterly) | -1.424B |
| Free Cash Flow | 10.16B |
| Free Cash Flow Per Share (Quarterly) | -0.238 |
| Free Cash Flow to Equity (Quarterly) | -465.86M |
| Free Cash Flow to Firm (Quarterly) | -959.66M |
| Free Cash Flow Yield | 1.75% |